Top

Published in:

01-11-2014 | Review

New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia

Authors: Saeid Shahrabi, Shirin Azizidoost, Mohammad Shahjahani, Fakher Rahim, Ahmad Ahmadzadeh, Najmaldin Saki

Published in: Tumor Biology | Issue 11/2014

Abstract

Hematoproliferative neoplasias like chronic myelogenous leukemia (CML) progressively affect bone marrow niche; however, there are only few specific clinical markers for prediction of disease progression. Here, we review the myeloproliferative niche and molecular changes including signaling pathways as well as microRNA (miRNA) in CML in order to better understand the therapeutic approaches. CML is a three-stage myeloproliferative disorder caused by reciprocal translocation between chromosome 9 and 22. There has been a new interest on treatment of this disorder. Therefore, in order to develop the appropriate therapy, an analysis of the molecular changes involved in malignant cells can be effective. A review of the signaling pathways, miRNA, and related targets can be helpful for better understanding of molecular pathogenesis of CML. Characterizing malignant cells and molecular changes with a focus on their targets may help researchers use molecular targets as effective therapeutic means for CML. On the other hand, interactions between leukemic stem cells and CML niche will help researchers investigate the causes of drug resistance in this disease.

Celso CL, Fleming HE, Wu JW, Zhao CX, Miake-Lye S, Fujisaki J, et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature. 2009;457(7225):92–6.PubMedCentralPubMedCrossRef

Azizidoost S, Babashah S, Rahim F, Shahjahani M, Saki N. Bone marrow neoplastic niche in leukemia. Hematology. 2014;19(4):232–8.PubMedCrossRef

Yasumizu R, Toki J, Asou H, Nishino T, Komatsu Y, Ikehara S. Production of hematopoietic stem cell-chemotactic factor by bone marrow stromal cells. Blood. 1994;83(4):964–71.PubMed

Williams DA, Cancelas JA. Leukaemia: niche retreats for stem cells. Nature. 2006;444(7121):827–8.PubMedCrossRef

Saki N, Abroun S, Farshdousti Hagh M, Asgharei F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J. 2011;13(3):131–6.PubMedCentralPubMed

Azizidoost S, Shanaki Bavarsad M, Shanaki Bavarsad M, Shahrabi S, Jaseb K, Rahim F, et al. The role of notch signaling in bone marrow niche. Hematology. 2014. doi:10.1179/1607845414y.0000000167.

Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013;13(3):285–99.PubMedCentralPubMedCrossRef

Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE, Radich JP. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 2009;114(15):3292–8.PubMedCentralPubMedCrossRef

Nwajei F, Konopleva M. The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol. 2013;2013.

10.

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med. 2001;344(14):1031–7.PubMedCrossRef

11.

Gordon JE, Wong JJL, Rasko JE. MicroRNAs in myeloid malignancies. Br J Haematol. 2013;162(2):162–76.PubMedCrossRef

12.

Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010;95(8):1325–33.PubMedCentralPubMedCrossRef

13.

Sipkins DA, Wei X, Wu JW, Runnels JM, Cote D, Means TK, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435(7044):969–73.PubMedCentralPubMedCrossRef

14.

Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu L, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6(12):1830–40.PubMedCrossRef

15.

Melo JV, Deininger MW. Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004;18(3):545–68.PubMedCrossRef

16.

Ahmed W, Van Etten RA. Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep. 2013;8(1):71–80.PubMedCrossRef

17.

Zhang B, Ho YW, Huang Q, Maeda T, Lin A, S-u L, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21(4):577–92.PubMedCentralPubMedCrossRef

18.

Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006;12(10):1175–80.PubMedCrossRef

19.

Ninomiya S, Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, et al. Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis. Int J Hematol. 2011;93(6):806–10.PubMedCrossRef

20.

Werner M, Kaloutsi V, Buhr T, Delventhal S, Vykoupil K-F, Georgii A. Cytogenetics of chronic myelogenous leukemia (CML) correlated to the histopathology of bone marrow biopsies. Ann Hematol. 1991;63(4):201–5.PubMedCrossRef

21.

Van der Plas D, Grosveld G, Hagemeijer A. Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML. Cancer Genet Cytogenet. 1991;52(2):143–56.PubMedCrossRef

22.

Provan A, Majer RV, Herbert A, Smith AG. del (15) (q11q15) associated with transformation of chronic myelomonocytic leukemia. Cancer Genet Cytogenet. 1991;55(1):35–8.PubMedCrossRef

23.

Wessels J, Fibbe W, Van Der Keur D, Landegent J, Van Der Plas D, Den Ottolander G, et al. t(5; 12)(q31; p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. Cancer Genet Cytogenet. 1993;65(1):7–11.PubMedCrossRef

24.

Sherrington P, Nacheva E, Fischer P, Rees J, Hoyle C, Dyer M, et al. Translocation 5;21 and interstitial deletion of chromosome 7 in a case of chronic myelomonocytic leukemia. Cancer Genet Cytogenet. 1988;31(2):247–52.PubMedCrossRef

25.

Medeiros BC, Markovic V, Kamel-Reid S, Lipton JH. Presence of t(1;14)(p13;p11.2) in Philadelphia chromosome-negative cells in a patient with chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;173(1):83–4.PubMedCrossRef

26.

Thompson P, Whittaker J. Translocation 3;21 in Philadelphia chromosome positive chronic myeloid leukemia at diagnosis. Cancer Genet Cytogenet. 1989;39(2):143–6.PubMedCrossRef

27.

Vaidya S, Joshi D, Ghosh K, Chakrabarti P, Vundinti BR. A novel 5-way translocation t(9;11;13;19;22) in a case of chronic-phase chronic myeloid leukemia. Hum Pathol. 2013;44(10):2365–9.PubMedCrossRef

28.

Gerber JM, Qin L, Kowalski J, Smith BD, Griffin CA, Vala MS, et al. Characterization of chronic myeloid leukemia stem cells. Am J Hematol. 2011;86(1):31–7.PubMedCentralPubMedCrossRef

29.

Gerber JM, Gucwa JL, Esopi D, Gurel M, Haffner MC, Vala M, et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013;4(5):715.PubMedCentralPubMed

30.

Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463(7281):676–80.PubMedCrossRef

31.

Corrêa S, Binato R, Du Rocher B, Castelo-Branco MT, Pizzatti L, Abdelhay E. Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer. 2012;12(1):303.PubMedCentralPubMedCrossRef

32.

Sengupta A, Banerjee D, Chandra S, Banerji S, Ghosh R, Roy R, et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia. 2007;21(5):949–55.PubMed

33.

Danisz K, Blasiak J. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors. Acta Biochim Pol. 2013;60:503–14.PubMed

34.

Yang Z, Yang C, Zhang S, Li Y, Chen J. Notch2 inhibits proliferation of chronic myeloid leukemia cells. Oncol Lett. 2013;5(4):1390–4.PubMedCentralPubMed

35.

Chang G, Zhang H, Wang J, Zhang Y, Xu H, Wang C, et al. CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells. Cancer Cell Int. 2013;13(1):117.PubMedCentralPubMedCrossRef

36.

Helgason GV, Young GA, Holyoake TL. Targeting chronic myeloid leukemia stem cells. Curr Hematol Malig Rep. 2010;5(2):81–7.PubMedCrossRef

37.

Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci. 2006;103(24):9136–41.PubMedCentralPubMedCrossRef

38.

Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13(6):496–506.PubMedCrossRef

39.

Polakova KM, Lopotová T, Klamová H, Burda P, Trněný M, Stopka T, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011;10(1):41–53.CrossRef

40.

Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140(5):652–65.PubMedCentralPubMedCrossRef

41.

Albano F, Anelli L, Zagaria A, Liso V, Rocchi M, Specchia G. MIRN199B downregulation in chronic myeloid leukaemia is associated with deletions on der(9). Br J Haematol. 2009;144(2):271–3.PubMedCrossRef

42.

Kong W, He L, Richards E, Challa S, Xu C, Permuth-Wey J, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2013;33(6):679–89.PubMedCentralPubMedCrossRef

43.

San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8(1):69–72.PubMedCentralPubMedCrossRef

44.

Zhu X, Lin Z, Du J, Zhou X, Yang L, Liu G. Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia. Mol Cell Biochem. 2014;390(1–2):75–84.PubMedCrossRef

45.

Babashah S, Sadeghizadeh M, Hajifathali A, Tavirani MR, Zomorod MS, Ghadiani M, et al. Targeting of the signal transducer Smo links microRNA‐326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells. Int J Cancer. 2013;133(3):579–89.PubMedCrossRef

46.

Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, et al. Expression of the miR-17–92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109(10):4399–405.PubMedCrossRef

47.

Li Y, Wang H, Tao K, Xiao Q, Huang Z, Zhong L, et al. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein. Exp Cell Res. 2013;319(8):1094–101.PubMedCrossRef

48.

Yin H, Liu Y, Zheng W-L, Song Y-B. Effects of miRNA-196b overexpression on proliferation, apoptosis and survivin, Cox-2 expression of K562 cells. China Oncol. 2013;5:007.

49.

Labbaye C, Testa U. The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. J Hematol Oncol. 2012;5(1):13.PubMedCentralPubMedCrossRef

50.

Chomel J, Aggoune D, Sorel N, Turhan A. [Chronic myeloid leukemia stem cells: cross-talk with the niche]. Med Sci: M/S. 2014;30(4):452–61.

51.

Corrado C, Raimondo S, Saieva L, Flugy AM, De Leo G, Alessandro R. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells. Cancer Lett. 2014;348(1):71–6.PubMedCrossRef

Title: New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia
Authors: Saeid Shahrabi
Shirin Azizidoost
Mohammad Shahjahani
Fakher Rahim
Ahmad Ahmadzadeh
Najmaldin Saki
Publication date: 01-11-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2610-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2014

RETRACTED ARTICLE: Betulin inhibits lung carcinoma proliferation through activation of AMPK signaling

Primary epidural hemangiopericytoma in the sacrum: a rare case and literature review

Association between murine double minute 2 T309G polymorphism and risk of liver cancer

Expression and clinical significance of microRNA-152 in supragalottic laryngeal carcinoma

TES was epigenetically silenced and suppressed the epithelial–mesenchymal transition in breast cancer

Molecular regulation of ovarian cancer cell invasion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer